Statement of the Spanish interdisciplinary vascular prevention committee on the updated European guidelines on cardiovascular disease prevention 2021

被引:0
|
作者
Brotons, C. [1 ]
Camafort, M. [2 ]
Castellanos, M. del Mar [3 ]
Clara, A. [4 ]
Cortes, O. [5 ]
Rodriguez, A. Diaz [6 ]
Elosua, R. [7 ]
Gorostidi, M. [8 ]
Hernandez, A. M. [9 ]
Herranz, M. [10 ]
Justo, S. [11 ]
Lahoz, C. [2 ]
Nino, P. [12 ]
Pallares-Carratala, V [6 ]
Pedro-Botet, J. [13 ]
Perez, A. Perez [9 ]
Royo-Bordonada, M. A. [14 ]
Santamaria, R. [8 ]
Tresserras, R. [15 ]
Zamora, A. [13 ]
Zuza, I [11 ]
Armario, P. [16 ]
机构
[1] Soc Espanola Med Familia & Comunitaria SemFYC, Barcelona, Spain
[2] Soc Espanola Med Interna, Barcelona, Spain
[3] Soc Espanola Neurol, Barcelona, Spain
[4] Soc Espanola Angiol & Cirugia Vasc, Madrid, Spain
[5] Assoc Espanola Pediat Atenc Primaria, Madrid, Spain
[6] Soc Espanola Med Atenc Primaria SEMERGEN, Madrid, Spain
[7] Soc Espanola Epidemiol, Barcelona, Spain
[8] Soc Espanola Nefrol, Santander, Spain
[9] Soc Espanola Diabet, Madrid, Spain
[10] Federac Asociac Enfermeria Comunitaria & Atenc Pr, Madrid, Spain
[11] Minist Sanidad, Madrid, Spain
[12] Soc Espanola Med & Seguridad Trabajo, Madrid, Spain
[13] Soc Espanola Arteriosclerosis, Barcelona, Spain
[14] Inst Salud Carlos III, Madrid, Spain
[15] Soc Espanola Salud Publ & Adm Sanitaria SESPAS, Barcelona, Spain
[16] Soc Espanola Liga Espanola Para Lucha Hipertens, Madrid, Spain
来源
ANGIOLOGIA | 2022年 / 74卷 / 05期
关键词
Prevention and control; Vascular diseases; Clinical practice guidelines; Healthy diet; Arterial hypertension; Diabetes; Lipid control; Smoking; Cardiovascular risk; THERAPY; SOCIETY;
D O I
10.20960/angiologia.00411
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease (CVD) prevention in clinical practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global CVD risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-Cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (Step 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After Step 1, considering proceeding to the intensified goals of Step 2 is mandatory, and this intensification will be based on 10-year CVD risk, lifetime CVD risk and treatment benefit, comorbidities and patient preferences. The updated SCORE algorithm (SCORE2 and SCORE-OP) is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal CVD events (myocardial infarction, stroke) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according different age groups (< 50, 50-69, >= 70 years). Different flow charts of CVD risk and risk factor treatment in apparently healthy persons, in patients with established atherosclerotic CVD, and in diabetic patients are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included.
引用
收藏
页码:237 / 248
页数:12
相关论文
共 50 条
  • [41] Canadian Cardiovascular Society position statement - Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease
    McPherson, Ruth
    Frohlich, Jiri
    Fodor, George
    Genest, Jacques
    CANADIAN JOURNAL OF CARDIOLOGY, 2006, 22 (11) : 913 - 927
  • [42] Summary of the European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Prepared by the Czech Society of Cardiology
    Cifkova, Renata
    Vaverkova, Helena
    Filipovsky, Jan
    Aschermann, Michael
    COR ET VASA, 2014, 56 (02) : E169 - E189
  • [43] Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?
    Ceska, Richard
    Stulc, Tomas
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (09) : 1180 - 1184
  • [44] Primary prevention of cardiovascular disease with aspirin: what do the guidelines say?
    Brotons Cuixart, Carlos
    Moral Pelaez, Irene
    ATENCION PRIMARIA, 2010, 42 (09): : 470 - 481
  • [45] Simplified lipid guidelines Prevention and management of cardiovascular disease in primary care
    Allan, G. Michael
    Lindblad, Adrienne J.
    Comeau, Ann
    Coppola, John
    Hudson, Brianne
    Mannarino, Marco
    McMinis, Cindy
    Padwal, Raj
    Schelstraete, Christine
    Zarnke, Kelly
    Garrison, Scott
    Cotton, Candra
    Korownyk, Christina
    McCormack, James
    Nickel, Sharon
    Kolber, Michael R.
    CANADIAN FAMILY PHYSICIAN, 2015, 61 (10) : 857 - 867
  • [46] Adherence to clinical guidelines in management of diabetes and prevention of cardiovascular disease in Qatar
    Diab, Mohammad Issam
    Johnson, B. Julienne
    Hudson, Steve
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (01) : 101 - 112
  • [47] Global perspectives on heart disease rehabilitation and secondary prevention: a scientific statement from the Association of Cardiovascular Nursing and Allied Professions, European Association of Preventive Cardiology, and International Council of Cardiovascular Prevention and Rehabilitation
    Taylor, Rod S.
    Fredericks, Suzanne
    Jones, Ian
    Neubeck, Lis
    Sanders, Julie
    De Stoutz, Noemi
    Thompson, David R.
    Wadhwa, Deepti N.
    Grace, Sherry L.
    EUROPEAN HEART JOURNAL, 2023, 44 (28) : 2515 - 2525
  • [48] European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)
    Perk J.
    De Backer G.
    Gohlke H.
    Graham I.
    Reiner Z.
    Verschuren W.M.M.
    Albus C.
    Benlian P.
    Boysen G.
    Cifkova R.
    Deaton C.
    Ebrahim S.
    Fisher M.
    Germano G.
    Hobbs R.
    Hoes A.
    Karadeniz S.
    Mezzani A.
    Prescott E.
    Ryden L.
    Scherer M.
    Syvänne M.
    Op Reimer W.J.M.S.
    Vrints C.
    Wood D.
    Zamorano J.L.
    Zannad F.
    International Journal of Behavioral Medicine, 2012, 19 (4) : 403 - 488
  • [49] European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology
    Aktaa, Suleman
    Gencer, Baris
    Arbelo, Elena
    Davos, Constantinos H.
    Desormais, Ileana
    Hollander, Monika
    Abreu, Ana
    Ambrosetti, Marco
    Back, Maria
    Carballo, David
    Crawford, Carolyn
    Deaton, Christi
    Dendale, Paul
    Eijsvogels, Thijs M. H.
    Galbraith, Mary
    Piepoli, Massimo Francesco
    Salzwedel, Annett
    Smulders, Yvo
    Wilhelm, Matthias
    Biondi-Zoccai, Giuseppe
    Mach, Francois
    Visseren, Frank L. J.
    Gale, Chris P.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (07) : 1060 - 1071
  • [50] Prescribing Statins for Cardiovascular Disease Prevention in the Old: An Absence of Evidence and an Absence of Guidelines
    Noaman, Samer
    Ibrahim, Joseph E.
    Grenfell, Robert
    HEART LUNG AND CIRCULATION, 2014, 23 (07) : 619 - 624